Loading
When a treatment stops working, the tumour is rarely re-sampled, so nobody learns why. Paying for a biopsy at that moment would build the missing map of resistance.
Resistance mechanisms are known for only a minority of progressions because the sample is never taken: reimbursement is unclear, the patient is unwell, and there is no trial slot. A funded pathway would pay for a paired tissue and plasma sample at every progression on a targeted agent, with rapid sequencing, a mechanism-matched treatment recommendation returned to the clinician, and deposition into a shared database.
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy, Comprehensive genomic profiling.
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Circulating tumour DNA (ctDNA), Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Acquired resistance to every therapy, Comprehensive genomic profiling, Liquid biopsy (ctDNA).
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.